Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden.
Max Planck Institute for Molecular Biomedicine, Münster, Germany.
Elife. 2021 Apr 28;10:e64944. doi: 10.7554/eLife.64944.
Hypoxia and consequent production of vascular endothelial growth factor A (VEGFA) promote blood vessel leakiness and edema in ocular diseases. Anti-VEGFA therapeutics may aggravate hypoxia; therefore, therapy development is needed.
Oxygen-induced retinopathy was used as a model to test the role of nitric oxide (NO) in pathological neovascularization and vessel permeability. Suppression of NO formation was achieved chemically using L-NMMA, or genetically, in endothelial NO synthase serine to alanine (S1176A) mutant mice.
Suppression of NO formation resulted in reduced retinal neoangiogenesis. Remaining vascular tufts exhibited reduced vascular leakage through stabilized endothelial adherens junctions, manifested as reduced phosphorylation of vascular endothelial (VE)-cadherin Y685 in a c-Src-dependent manner. Treatment with a single dose of L-NMMA in established retinopathy restored the vascular barrier and prevented leakage.
We conclude that NO destabilizes adheren junctions, resulting in vascular hyperpermeability, by converging with the VEGFA/VEGFR2/c-Src/VE-cadherin pathway.
This study was supported by the Swedish Cancer foundation (19 0119 Pj ), the Swedish Research Council (2020-01349), the Knut and Alice Wallenberg foundation (KAW 2020.0057) and a Fondation Leducq Transatlantic Network of Excellence Grant in Neurovascular Disease (17 CVD 03). KAW also supported LCW with a Wallenberg Scholar grant (2015.0275). WCS was supported by Grants R35 HL139945, P01 HL1070205, AHA MERIT Award. DV was supported by grants from the Deutsche Forschungsgemeinschaft, SFB1450, B03, and CRU342, P2.
缺氧和随之产生的血管内皮生长因子 A(VEGFA)促进了眼部疾病中血管的通透性增加和水肿。抗 VEGFA 疗法可能会加重缺氧;因此,需要开发新的治疗方法。
氧诱导的视网膜病变被用作模型,以测试一氧化氮(NO)在病理性新生血管形成和血管通透性中的作用。通过化学方法使用 L-NMMA 或内皮型一氧化氮合酶丝氨酸到丙氨酸(S1176A)突变小鼠进行基因抑制来抑制 NO 的形成。
抑制 NO 的形成导致视网膜新生血管生成减少。残留的血管丛表现出血管渗漏减少,这是通过内皮细胞黏附连接的稳定化来实现的,表现为血管内皮(VE)-钙黏蛋白 Y685 的磷酸化程度降低,这种降低方式依赖于 c-Src。在已建立的视网膜病变中单次给予 L-NMMA 治疗可恢复血管屏障并防止渗漏。
我们的结论是,NO 通过与 VEGFA/VEGFR2/c-Src/VE-cadherin 通路相融合,破坏黏附连接,导致血管通透性增加。
本研究得到了瑞典癌症基金会(19 0119 Pj)、瑞典研究委员会(2020-01349)、Knut 和 Alice Wallenberg 基金会(KAW 2020.0057)和神经血管疾病跨大西洋卓越网络卓越基金会(17 CVD 03)的资助。KAW 还通过 Wallenberg 学者基金(2015.0275)资助 LCW。WCS 得到了美国国立卫生研究院 R35 HL139945、P01 HL1070205 和 AHA MERIT 奖的资助。DV 得到了德国研究基金会(DFG)的 SFB1450、B03 和 CRU342、P2 项目的资助。